The specifics, since they change the answer: liraglutide · ten weeks · 4 °C.
I would like to define my thresholds before I have a result, for obvious reasons.
I want a plan with explicit stopping rules, not just steps.
What is the minimum version of this that is still defensible?
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
Stated carefully, under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemMore usefully, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Worth being precise here: a statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If testing multiple vials, state how many you tested and why you chose those vials.
If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 17 Sept 2024 by b_delacroix — clarified the distinction between purity and content
To be exact about it, the practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
It helps to be literal here: start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
If testing multiple vials, state how many you tested and why you chose those vials.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.